Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431974 · ClinicalTrials.gov registry record · Phase 2
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
A Phase 2 study, sponsored by Syntrix Biosystems.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03431974 is a Phase 2 study that has completed, run by Syntrix Biosystems. The registered enrollment target is 19 participants.
The verdict
NCT03431974, a Phase 2 study, has completed, sponsored by Syntrix Biosystems.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated with aminopterin or placebo.
Interventions
- DRUG Placebo oral capsule
- DRUG LD-Aminopterin oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431974
The ClinicalTrials.gov registry entry for NCT03431974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syntrix Biosystems, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03431974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03431974 about?
NCT03431974 is a clinical study titled "Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis". This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated with aminopterin or placebo.
What is the current status of trial NCT03431974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-11-01. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT03431974?
The interventions under investigation include: Placebo oral capsule (DRUG), LD-Aminopterin oral capsule (DRUG).
Who is sponsoring clinical trial NCT03431974?
This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.